Author Archives: pancreatica
Mitazalimab receives orphan Status for pancreatic cancer
Mitazalimab is a monoclonal antibody that targets CD40, a protein that is expressed on the surface of many types of cancer cells. CD40 signaling is thought to play a role in tumor growth and metastasis. Mitazalimab works by blocking CD40 signaling, which can lead to tumor cell death. The FDA has granted orphan drug designation […]
The Enzyme Returns: L-asparaginase encased in red blood cells for pancreatic cancer
In late March 2017, the French biotech firm Erytech presented results of a IIb clinical trial of eryaspase (trade name: GRASPA) which is the enzyme l-asparaginase encapsulated in red blood cells as added to gemcitabine or FOLFIRINOX treatment regimens for patients with advanced pancreatic cancer (ductal adenocarcinoma of the pancreas), versus these standard therapies alone. […]